Noradrenaline and Parkinson's disease

Frontiers in Systems Neuroscience

Volumn , Issue MAY 2011, 2011, Pages

  Delaville, Claire ^a,b   de Deurwaerdère, Philippe ^a,b   Benazzouz, Abdelhamid ^a,b,c  

^a INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^b CNRS   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Dopamine; Locus coeruleus; Motor and non motor symptoms; Noradrenaline; Parkinson's disease

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; ANTIPARKINSON AGENT; ATIPAMEZOLE; ATOMOXETINE; BENSERAZIDE; CLONIDINE; DEXMEDETOMIDINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FIPAMEZOLE; IDAZOXAN; LEVODOPA; NAPHTHOXAZINE DERIVATIVE; NORADRENALIN; PROPRANOLOL; RAUWOLSCINE; REBOXETINE; THREO DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG; YOHIMBINE;

AKATHISIA; AKINESIA; ALERTNESS; ANXIETY; ATTENTION; ATTENTION DEFICIT DISORDER; BALANCE DISORDER; BRAIN NERVE CELL; DEMENTIA; DEPRESSION; DISEASE MODEL; DRUG INDUCED HEADACHE; DRUG MECHANISM; DYSKINESIA; EDITORIAL; FLUSHING; HUMAN; HYPERTENSION; LOCOMOTION; LOCUS CERULEUS; MOLECULAR INTERACTION; MUSCLE RIGIDITY; NONHUMAN; NORADRENALIN RELEASE; NORADRENERGIC SYSTEM; ON OFF PHENOMENON; PARKINSON DISEASE; PATHOPHYSIOLOGY; RECEPTOR INTRINSIC ACTIVITY; SIDE EFFECT; SYMPTOM; SYNAPTIC TRANSMISSION; TARDIVE DYSKINESIA; TREMOR;

EID: 84855813064     PISSN: 16625137     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnsys.2011.00031     Document Type: Editorial

References (155)

1. Amalric, M., Moukhles, H., Nieoullon, A., and Daszuta, A. (1995). Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur. J. Neurosci. 7, 972-980.
2. Arai, A., Tomiyama, M., Kannari, K., Kimura, T., Suzuki, C., Watanabe, M., Kawarabayashi, T., Shen, H., and Shoji, M. (2008). Reuptake of L-DOPA-derived extracellular DA in the stria-tum of a rodent model of Parkinson's disease via norepinephrine transporter. Synapse 62, 632-635.
3. Archer, T., and Fredriksson, A. (2006). Influence of noradrenaline den-ervation on MPTP-induced deficits in mice. J. Neural Transm. 113, 1119-1129.
4. Arcos, D., Sierra, A., Nunez, A., Flores, G., Aceves, J., and Arias-Montano, J. A. (2003). Noradrenaline increases the firing rate of a subpopulation of rat subthalamic neurones through the activation of alpha 1-adreno-ceptors. Neuropharmacology 45, 1070-1079.
5. Aston-Jones, G. (2004). "Locus coeruleus, A5 and A7 noradrenergic cell groups," in The Rat Nervous System, 3rd Edn, ed G. Paxinos (New York: Elsevier), 259-284.
6. Aston-Jones, G., and Cohen, J. D. (2005a). Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. J. Comp. Neurol. 493, 99-110.
7. Aston-Jones, G., and Cohen, J. D. (2005b). An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu. Rev. Neurosci. 28, 403-450.
8. Auclair, A., Cotecchia, S., Glowinski, J., and Tassin, J. P. (2002). D-amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release. J. Neurosci. 22, 9150-9154.
9. Azuma, T., Suzuki, T., Sakoda, S., Mizuno, R., Tsujino, S., Kobayashi, T., Kishimoto, S., Hiraga, T., Matsubara, T., Yoshida, S., and Tone, K. (1991). Effect of long-term L-threo-3, 4- dihydroxyphenylserine administration on alpha 2-adrenergic receptors in platelet membranes in neurologic disorders. Acta Neurol. Scand. 84, 46-50.
10. Bader, J. P., and Hell, D. (1998). [Parkinson syndrome and depression]. Fortschr. Neurol. Psychiatr. 66, 303-312.
11. Baloyannis, S. J., Costa, V., and Baloyannis, I. S. (2006). Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease. J. Neurol. Sci. 248, 35-41.
12. Bara-Jimenez, W., Dimitrova, T., Sherzai, A., Favit, A., Mouradian, M. M., and Chase, T. N. (2004). Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. Mov. Disord. 19, 1183-1186.
13. Bedard, M. A., el Massioui, F., Malapani, C., Dubois, B., Pillon, B., Renault, B., and Agid, Y. (1998). Attentional defcits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. Clin. Neuropharmacol. 21, 108-117.
14. Belujon, P., Bezard, E., Taupignon, A., Bioulac, B., and Benazzouz, A. (2007). Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxy-dopamine-lesioned rats. J. Neurosci. 27, 9595-9606.
15. Benarroch, E. E. (2009). The locus ceru-leus norepinephrine system: functional organization and potential clinical significance. Neurology 73, 1699-1704.
16. Benazzouz, A., Boraud, T., Feger, J., Burbaud, P., Bioulac, B., and Gross, C. (1996). Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment. Mov. Disord. 11, 627-632.
17. Benazzouz, A., Gross, C., Feger, J., Boraud, T., and Bioulac, B. (1993). Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur. J. Neurosci. 5, 382-389.
18. Bergman, H., Wichmann, T., and DeLong, M. R. (1990). Reversal of experimental parkinsonism by lesions of the subtha-lamic nucleus. Science 249, 1436-1438.
19. Berridge, C. W., and Waterhouse, B. D. (2003). The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res. Brain Res. Rev. 42, 33-84.
20. Bertrand, E., Lechowicz, W., Szpak, G. M., and Dymecki, J. (1997). Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol. 35, 80-86.
21. Bezard, E., Brefel, C., Tison, F., Peyro-Saint-Paul, H., Ladure, P., Rascol, O., and Gross, C. E. (1999). Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog. Neuropsychopharmacol. Biol. Psychiatry 23, 1237-1246.
22. Bezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., Crossman, A. R., Bioulac, B., Brotchie, J. M., and Gross, C. E. (2001). Relationship between the appearance of symptoms and the level of nigros-triatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21, 6853-6861.
23. Braak, H., and Del Tredici, K. (2008). Invited article: nervous system pathology in sporadic Parkinson disease. Neurolog y 70, 1916-1925.
24. Branchi, I., D'Andrea, I., Armida, M., Cassano, T., Pezzola, A., Potenza, R. L., Morgese, M. G., Popoli, P., and Alleva, E. (2008). Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J. Neurosci. Res. 86, 2050-2061.
25. Breit, S., Bouali-Benazzouz, R., Popa, R. C., Gasser, T., Benabid, A. L., and Benazzouz, A. (2007). Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat. Exp. Neurol. 205, 36-47.
26. Bxarone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., and Weintraub, D. (2010). Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 573-580.
27. Carroll, F. I., Scheffel, U., Dannals, R. F., Boja, J. W., and Kuhar, M. J. (1995). Development of imaging agents for the dopamine transporter. Med. Res. Rev. 15, 419-444.
28. Carta, M., Carlsson, T., Kirik, D., and Bjorklund, A. (2007). Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyski-nesia in parkinsonian rats. Brain 130, 1819-1833.
29. Cash, R., Dennis, T., L'Heureux, R., Raisman, R., Javoy-Agid, F., and Scatton, B. (1987). Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 37, 42-46.
30. Cash, R., Raisman, R., Lanfumey, L., Ploska, A., and Agid, Y. (1986). Cellular localization of adrenergic receptors in rat and human brain. Brain Res. 370, 127-135.
31. Cash, R., Ruberg, M., Raisman, R., and Agid, Y. (1984). Adrenergic receptors in Parkinson's disease. Brain Res. 322, 269-275.
32. Chan-Palay, V., and Asan, E. (1989). Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol. 287, 373-392.
33. Chaudhuri, K. R., and Odin, P. (2010). The challenge of non-motor symptoms in Parkinson's disease. Prog. Brain Res. 184, 325-341.
34. Chopin, P., Colpaert, F. C., and Marien, M. (1999). Effects of alpha-2 adreno-ceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 288, 798-804.
35. Colosimo, C., and Craus, A. (2003). Noradrenergic drugs for levo-dopa-induced dyskinesia. Clin. Neuropharmacol. 26, 299-305.
36. Colpaert, F. C. (1987). Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reser-pine in rat. Neuropharmacology 26, 1431-1440.
37. Cummings, J. L. (1992). Depression and Parkinson's disease: a review. Am. J. Psychiatry 149, 443-454.
38. Dailly, E., Chenu, F., Petit-Demouliere, B., and Bourin, M. (2006). Specifcity and effcacy of noradrenaline, serotonin depletion in discrete brain areas of Swiss mice by neurotoxins. J. Neurosci. Methods 150, 111-115.
39. Davis, M., Kehne, J. H., and Commissaris, R. L. (1985). Antagonism of apomorphine-enhanced startle by alpha 1-adrenergic antagonists. Eur. J. Pharmacol. 108, 233-241.
40. Delaville, C., Chetrit, J., Abdallah, K., Morin, S., Cardoit, L., De Deurwaerdère, P., and Benazzouz, A. (2010). Involvement of monoamine defciency in motor and nonmotor disabilities of Parkinson's disease: behavioural, biochemical and elec-trophysiological studies (Int. Basal Ganglia Soc. Abstr.).
41. De Leonibus, E., Pascucci, T., Lopez, S., Oliverio, A., Amalric, M., and Mele, A. (2007). Spatial defcits in a mouse model of Parkinson disease. Psychopharmacology (Berl.) 194, 517-525.
42. Deumens, R., Blokland, A., and Prickaerts, J. (2002). Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175, 303-317.
43. Devos, D., Defebvre, L., and Bordet, R. (2010). Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease. Fundam. Clin. Pharmacol. 24, 407-421.
44. Di Paolo, T., Bedard, P., Daigle, M., and Boucher, R. (1986). Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys. Brain Res. 379, 286-293.
45. Dooneief, G., Mirabello, E., Bell, K., Marder, K., Stern, Y., and Mayeux, R. (1992). An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch. Neurol. 49, 305-307.
46. Ehringer, H., and Hornykiewicz, O. (1960). [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin. Wochenschr. 38, 1236-1239.
47. Ehringer, H., and Hornykiewicz, O. (1998). Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat. Disord. 4, 53-57.
48. Fornai, F., di Poggio, A. B., Pellegrini, A., Ruggieri, S., and Paparelli, A. (2007). Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr. Med. Chem. 14, 2330-2334.
49. Fornai, F., Vaglini, F., Maggio, R., Bonuccelli, U., and Corsini, G. U. (1996). Excitatory amino acids and MPTP toxicity. Adv. Neurol. 69, 167-176.
50. Forno, L. S., Langston, J. W., DeLanney, L. E., Irwin, I., and Ricaurte, G. A. (1986). Locus ceruleus lesions and eosi-nophilic inclusions in MPTP-treated monkeys. Ann. Neurol. 20, 449-455.
51. Fox, S. H., and Brotchie, J. M. (2010). The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog. Brain Res. 184, 133-157.
52. Fox, S. H., Henry, B., Hill, M. P., Peggs, D., Crossman, A. R., and Brotchie, J. M. (2001). Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomor-phine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov. Disord. 16, 642-650.
53. Fritschy, J. M., and Grzanna, R. (1989). Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifes two populations of noradrenergic axon terminals. Neuroscience 30, 181-197.
54. Fritschy, J. M., and Grzanna, R. (1991). Selective effects of DSP-4 on locus coeruleus axons: are there pharmacologically different types of noradren-ergic axons in the central nervous system? Prog. Brain Res. 88, 257-268.
55. Fulceri, F., Biagioni, F., Ferrucci, M., Lazzeri, G., Bartalucci, A., Galli, V., Ruggieri, S., Paparelli, A., and Fornai, F. (2007). Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons. Brain Res. 1135, 219-229.
56. Gareri, P., De Fazio, P., and De Sarro, G. (2002). Neuropharmacology of depression in aging and age-related diseases. Ageing Res. Rev. 1, 113-134.
57. Gaspar, P. (1994). Anatomy of the Noradrenergic Pathways in the Primate Brain Alteration in Parkinson's Disease. Boca Raton: CRC Press, 73-88.
58. Gaspar, P., Duyckaerts, C., Alvarez, C., Javoy-Agid, F., and Berger, B. (1991). Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann. Neurol. 30, 365-374.
59. German, D. C., Manaye, K. F., White, C. L. III, Woodward, D. J., McIntire, D. D., Smith, W. K., Kalaria, R. N., and Mann, D. M. (1992). Disease-specifc patterns of locus coeruleus cell loss. Ann. Neurol. 32, 667-676.
60. Gomez-Mancilla, B., and Bedard, P. J. (1993). Effect of nondopaminergic drugs on L-dopa-induced dyskine-sias in MPTP-treated monkeys. Clin. Neuropharmacol. 16, 418-427.
61. Greenfield, J. G., and Bosanquet, F. D. (1953). The brain-stem lesions in Parkinsonism. J. Neurol. Neurosurg. Psychiatr. 16, 213-226.
62. Grimbergen, Y. A., Langston, J. W., Roos, R. A., and Bloem, B. R. (2009). Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev. Neurother. 9, 279-290.
63. Grondin, R., Hadj Tahar, A., Doan, V. D., Ladure, P., and Bedard, P. J. (2000). Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch. Pharmacol. 361, 181-186.
64. Grzanna, R., Berger, U., Fritschy, J. M., and Geffard, M. (1989). Acute action of DSP-4 on central norepinephrine axons: biochemical and immunohis-tochemical evidence for differential effects. J. Histochem. Cytochem. 37, 1435-1442.
65. Haapalinna, A., Leino, T., and Heinonen, E. (2003). The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn Schmiedebergs Arch. Pharmacol. 368, 342-351.
66. Hara, M., Fukui, R., Hieda, E., Kuroiwa, M., Bateup, H. S., Kano, T., Greengard, P., and Nishi, A. (2010). Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons. J. Neurochem. 113, 1046-1059.
67. Henry, B., Fox, S. H., Peggs, D., Crossman, A. R., and Brotchie, J. M. (1999). The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 14, 744-753.
68. Hill, M. P., and Brotchie, J. M. (1999). The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. Br. J. Pharmacol. 128, 1577-1585.
69. Hollister, A. S., Breese, G. R., and Mueller, R. A. (1979). Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity. J. Pharmacol. Exp. Ther. 208, 37-43.
70. Hornykiewicz, O. (1975). Brain monoam-ines and parkinsonism. Natl. Inst. Drug Abuse Res. Monogr. Ser. 11, 13-21.
71. Hudson, A. L., Robinson, E. S., Lalies, M. D., Tyacke, R. J., Jackson, H. C., and Nutt, D. J. (1999). In vitro and in vivo approaches to the characterization of the alpha2-adrenoceptor. J. Auton. Pharmacol. 19, 311-320.
72. Jankovic, J., and Talosa, E. (1988). Parkinson's Disease and Movement Disorders, 5th Edn. Baltimore: Lippincott William and Wilkins.
73. Javitch, J. A., Uhl, G. R., and Snyder, S. H. (1984). Parkinsonism-inducing neu-rotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain. Proc. Natl. Acad. Sci. U.S.A. 81, 4591-4595.
74. Jenner, P., Sheehy, M., and Marsden, C. D. (1983). Noradrenaline and 5-hydrox-ytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. Br. J. Clin. Pharmacol. 15(Suppl. 2), 277S-289S.
75. Johnson, E. W., Wolfe, B. B., and Molinoff, P. B. (1989). Regulation of subtypes of beta-adrenergic receptors in rat brain following treatment with 6-hydroxy-dopamine. J. Neurosci. 9, 2297-2305.
76. Kasper, S., el Giamal, N., and Hilger, E. (2000). Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin. Pharmacother. 1, 771-782.
77. Khakpour-Taleghani, B., Lashgari, R., Motamedi, F., and Naghdi, N. (2009). Effect of reversible inactivation of locus ceruleus on spatial reference and working memory. Neuroscience 158, 1284-1291.
78. Kirik, D., Rosenblad, C., and Bjorklund, A. (1998). Characterization of behavioral and neurodegenerative changes following partial lesions of the nigros-triatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152, 259-277.
79. Kish, S. J. (2003). Biochemistry of Parkinson's disease: is a brain sero-tonergic defciency a characteristic of idiopathic Parkinson's disease? Adv. Neurol. 91, 39-49.
80. Kish, S. J., Tong, J., Hornykiewicz, O., Rajput, A., Chang, L. J., Guttman, M., and Furukawa, Y. (2008). Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 131, 120-131.
81. Kuno, S. (1997). [Treatment of Parkinson's disease with multiple drugs]. Nippon Rinsho 55, 59-64.
82. Langston, J. W., and Ballard, P. (1984). Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can. J. Neurol. Sci. 11, 160-165.
83. Langston, J. W., and Ballard, P. A. Jr. (1983). Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 309, 310.
84. Lapiz, M. D., Mateo, Y., Durkin, S., Parker, T., and Marsden, C. A. (2001). Effects of central noradrenaline depletion by the selective neurotoxin DSP-4 on the behaviour of the isolated rat in the elevated plus maze and water maze. Psychopharmacology (Berl.) 155, 251-259.
85. Lauterbach, E. C., Freeman, A., and Vogel, R. L. (2003). Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease. Cogn. Behav. Neurol. 16, 225-233.
86. Lemke, M. R. (2002). Effect of rebox-etine on depression in Parkinson's disease patients. J. Clin. Psychiatry 63, 300-304.
87. Lemke, M. R., Fuchs, G., Gemende, I., Herting, B., Oehlwein, C., Reichmann, H., Rieke, J., and Volkmann, J. (2004). Depression and Parkinson's disease. J. Neurol. 251(Suppl. 6), 24-27.
88. Mann, D. M. (1983). The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech. Ageing Dev. 23, 73-94.
89. Mann, D. M., and Yates, P. O. (1983). Pathological basis for neurotrans-mitter changes in Parkinson's disease. Neuropathol. Appl. Neurobiol. 9, 3-19.
90. Marie, R. M., Barre, L., Rioux, P., Allain, P., Lechevalier, B., and Baron, J. C. (1995). PET imaging of neocortical monoam-inergic terminals in Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 9, 55-71.
91. Marien, M. R., Colpaert, F. C., and Rosenquist, A. C. (2004). Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev. 45, 38-78.
92. Maruyama, W., Naoi, M., and Narabayashi, H. (1996). The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fuid from parkinsonian patients. J. Neurol. Sci. 139, 141-148.
93. Mathe, J. M., Nomikos, G. G., Hildebrand, B. E., Hertel, P., and Svensson, T. H. (1996). Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309, 1-11.
94. Mavridis, M., Degryse, A. D., Lategan, A. J., Marien, M. R., and Colpaert, F. C. (1991). Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41, 507-523.
95. Mayeux, R., Stern, Y., Sano, M., Cote, L., and Williams, J. B. (1987). Clinical and biochemical correlates of bradyphre-nia in Parkinson's disease. Neurology 37, 1130-1134.
96. Mayeux, R., Stern, Y., Williams, J. B., Cote, L., Frantz, A., and Dyrenfurth, I. (1986). Clinical and biochemical features of depression in Parkinson's disease. Am. J. Psychiatry 143, 756-759.
97. McCormick, D. A. (1992). Neurotransmitter actions in the tha-lamus and cerebral cortex. J. Clin. Neurophysiol. 9, 212-223.
98. McCormick, D. A., Pape, H. C., and Williamson, A. (1991). Actions of norepinephrine in the cerebral cortex and thalamus: implications for function of the central noradrenergic system. Prog. Brain Res. 88, 293-305.
99. McCormick, D. A., and Wang, Z. (1991). Serotonin and noradrenaline excite GABAergic neurones of the guinea-pig and cat nucleus reticularis thalami. J. Physiol. 442, 235-255.
100. McNamara, P., and Durso, R. (2006). Neuropharmacological treatment of mental dysfunction in Parkinson's disease. Behav. Neurol. 17, 43-51.
101. Mitchell, I. J., Cross, A. J., Sambrook, M. A., and Crossman, A. R. (1985). Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci. Lett. 61, 195-200.
102. Miyoshi, R., Kito, S., Ishida, H., and Katayama, S. (1988). Alterations of the central noradrenergic system in MPTP-induced monkey parkinson-ism. Res. Commun. Chem. Pathol. Pharmacol. 62, 93-102.
103. Mizuno, Y., Kondo, T., and Mori, H. (1994). Various aspects of motor fuctuations and their management in Parkinson's disease. Neurology 44, S29-S34.
104. Narabayashi, H., Yokochi, F., Ogawa, T., and Igakura, T. (1991). [Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease]. No To Shinkei 43, 263-268.
105. Navailles, S., Bioulac, B., Gross, C., and De Deurwaerdere, P. (2010a). Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol. Dis. 41, 585-590.
106. Navailles, S., Bioulac, B., Gross, C., and De Deurwaerdere, P. (2010b). Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol. Dis. 38, 136-143.
107. Nishi, K., Kondo, T., and Narabayashi, H. (1991). Destruction of norepine-phrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces loco-motor activity induced by L-dopa. Neurosci. Lett. 123, 244-247.
108. Oertel, W. H., Hoglinger, G. U., Caraceni, T., Girotti, F., Eichhorn, T., Spottke, A. E., Krieg, J. C., and Poewe, W. (2001). Depression in Parkinson's disease. An update. Adv. Neurol. 86, 373-383.
109. Ogawa, N., Kuroda, H., Yamamoto, M., Nukina, I., and Ota, Z. (1984). Improvement in freezing phenom-DL-threo-3, 4-dihydroxyphenyl-serine. Acta Med. Okayama 38, 301-304.
110. Ogawa, N., Yamamoto, M., and Takayama, H. (1985). L-threo-3, 4-dihydroxyphe-nylserine treatment of Parkinson's disease. J. Med. 16, 525-534.
111. Olsson, M., Nikkhah, G., Bentlage, C., and Bjorklund, A. (1995). Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 15, 3863-3875.
112. Perez, V., Marin, C., Rubio, A., Aguilar, E., Barbanoj, M., and Kulisevsky, J. (2009a). Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances. J. Neural Transm. 116, 1257-1266.
113. Perez, V., Sosti, V., Rubio, A., Barbanoj, M., Gich, I., Rodriguez-Alvarez, J., and Kulisevsky, J. (2009b). Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats. J. Neural Transm. 116, 867-874.
114. Perez, V., Sosti, V., Rubio, A., Barbanoj, M., Rodriguez-Alvarez, J., and Kulisevsky, J. (2007). Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration. Eur. J. Pharmacol. 576, 83-90.
115. Pifl, C., Schingnitz, G., and Hornykiewicz, O. (1991). Effect of 1 -methy l- 4- phenyl-1,2,3, 6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 44, 591-605.
116. Politis, M., Wu, K., Loane, C., Kiferle, L., Molloy, S., Brooks, D. J., and Piccini, P. (2010). Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol. Dis. 40, 216-221.
117. Ponzio, F., Hallman, H., and Jonsson, G. (1981). Noradrenaline and dopamine interaction in rat brain during development. Med. Biol. 59, 161-169.
118. Rascol, O., Arnulf, I., Peyro-Saintpaul, H., Brefel-Courbon, C., Vidailhet, M., Thalamas, C., Bonnet, A. M., Descombes, S., Bejjani, B., Fabre, N., Montastruc, J. L., and Agid, Y. (2001). Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov. Disord. 16, 708-713.
119. Rascol, O., Fabre, N., Blin, O., Poulik, J., Sabatini, U., Senard, J. M., Ane, M., Montastruc, J. L., and Rascol, A. (1994). Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov. Disord. 9, 437-440.
120. Reches, A., and Meiner, Z. (1992). The locus coeruleus and dopaminergic function in rat brain: implications to parkinsonism. Brain Res. Bull. 28, 663-666.
121. Remy, P., Doder, M., Lees, A., Turjanski, N., and Brooks, D. (2005). Depression in Parkinson's disease: loss of dopamine and noradrenaline inner-vation in the limbic system. Brain 128, 1314-1322.
122. Riekkinen, M., Kejonen, K., Jakala, P., Soininen, H., and Riekkinen, P. Jr. (1998). Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease. Eur. J. Neurosci. 10, 1429-1435.
123. Ringendahl, H., and Sierla, T. (1997). [Freezing phenomenon in Parkinson disease]. Fortschr. Neurol. Psychiatr. 65, 435-445.
124. Rommelfanger, K. S., and Weinshenker, D. (2007). Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem. Pharmacol. 74, 177-190.
125. Rommelfanger, K. S., Weinshenker, D., and Miller, G. W. (2004). Reduced MPTP toxicity in noradrenaline transporter knockout mice. J. Neurochem. 91, 1116-1124.
126. Ruckert, N., Bubser, M., and Schmidt, W. J. (1997). 6-Hydroxydopamine lesion of locus coeruleus and the antiparkin-sonian potential of NMDA-receptor antagonists in rats. J. Neural Transm. 104, 363-377.
127. Sandyk, R. (1996). Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields. Int. J. Neurosci. 85, 111-124.
128. Saper, C. B., Sorrentino, D. M., German, D. C., and de Lacalle, S. (1991). Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease. Ann. Neurol. 29, 577-584.
129. Savola, J. M., Hill, M., Engstrom, M., Merivuori, H., Wurster, S., McGuire, S. G., Fox, S. H., Crossman, A. R., and Brotchie, J. M. (2003). Fipamezole (JP-1730) is a potent alpha2 adrener-gic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 18, 872-883.
130. Schapira, A. H. (2005). Present and future drug treatment for Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 76, 1472-1478.
131. Schrag, A., Jahanshahi, M., and Quinn, N. P. (2001). What contributes to depression in Parkinson's disease? Psychol. Med. 31, 65-73.
132. Selikhova, M. V., Kogan, B. M., Serkin, G. V., and Gusev, E. I. (2002). [Catecholamine metabolism in different forms of Parkinson's disease]. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova. 102, 37-40.
133. Snoddy, A. M., and Tessel, R. E. (1985). Prazosin: effect on psychomotor-stimulant cues and locomotor activity in mice. Eur. J. Pharmacol. 116, 221-228.
134. Srinivasan, J., and Schmidt, W. J. (2003). Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of sub-stantia nigra in rats. Eur. J. Neurosci. 17, 2586-2592.
135. Stein, M. B., Heuser, I. J., Juncos, J. L., and Uhde, T. W. (1990). Anxiety disorders in patients with Parkinson's disease. Am. J. Psychiatry 147, 217-220.
136. Stern, Y., Mayeux, R., and Cote, L. (1984). Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism. Arch Neurol. 41, 1086-1089.
137. Suzuki, T., Sakoda, S., Ueji, M., Kishimoto, S., Hayashi, A., Kondo, T., and Narabayashi, H. (1984). Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacok-inetic study. Neurology 34, 1446-1450.
138. Tadaiesky, M. T., Dombrowski, P. A., Figueiredo, C. P., Cargnin-Ferreira, E., Da Cunha, C., and Takahashi, R. N. (2008). Emotional, cognitive and neu-rochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 156, 830-840.
139. Tanaka, H., Kannari, K., Maeda, T., Tomiyama, M., Suda, T., and Matsunaga, M. (1999). Role of sero-tonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10, 631-634.
140. Tanda, G., Pontieri, F. E., Frau, R., and Di Chiara, G. (1997). Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur. J. Neurosci. 9, 2077-2085.
141. Taquet, H., Javoy-Agid, F., Cesselin, F., Hamon, M., Legrand, J. C., and Agid, Y. (1982). Microtopography of methionine-enkephalin, dopamine and noradrenaline in the ventral mesencephalon of human control and Parkinsonian brains. Brain Res. 235, 303-314.
142. Taylor, T. N., Caudle, W. M., Shepherd, K. R., Noorian, A., Jackson, C. R., Iuvone, P. M., Weinshenker, D., Greene, J. G., and Miller, G. W. (2009). Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 29, 8103-8113.
143. Thomas, S. A., Matsumoto, A. M., and Palmiter, R. D. (1995). Noradrenaline is essential for mouse fetal development. Nature 374, 643-646.
144. Tohgi, H., Abe, T., Saheki, M., Yamazaki, K., and Murata, T. (1997). Concentration of catecholamines and indoleamines in the cerebrospinal fuid of patients with vascular parkinsonism compared to Parkinson's disease patients. J. Neural Transm. 104, 441-449.
145. Tohgi, H., Abe, T., and Takahashi, S. (1993). The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fuid and freezing gait in parkinsonian patients. J. Neural Transm. Park. Dis. Dement. Sect. 5, 27-34.
146. Tohgi, H., Abe, T., Takahashi, S., Takahashi, J., Ueno, M., and Nozaki, Y. (1990). Effect of a synthetic nore-pinephrine precursor, L-threo-3,4-dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fuid of parkinsonian patients. Neurosci. Lett. 116, 194-197.
147. Wang, T., Zhang, Q. J., Liu, J., Wu, Z. H., and Wang, S. (2009). Firing activity of locus coeruleus noradrenergic neurons increases in a rodent model of Parkinsonism. Neurosci. Bull. 25, 15-20.
148. Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., and Stern, M. B. (2010). Atomoxetine for depression and other neuropsychi-atric symptoms in Parkinson disease. Neurology 75, 448-455.
149. Wilbur, R., Kulik, F. A., and Kulik, A. V. (1988). Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia. Prog. Neuropsychopharmacol. Biol. Psychiatry 12, 849-864.
150. Yamamoto, M. (2004). [Depression in Parkinson's disease]. Nippon Rinsho 62, 1661-1666.
151. Yamamoto, M., Ogawa, N., and Ujike, H. (1986). Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fuid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease. J. Neurol. Sci. 73, 39-44.
152. Yamazaki, M., Tanaka, C., and Takaori, S. (1979). Significance of central noradrenergic system on harmaline induced tremor. Pharmacol. Biochem. Behav. 10, 421-427.
153. Yavich, L., Sirvio, J., Haapalinna, A., Ylinen, A., and Mannisto, P. T. (2003). Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum. Eur. J. Pharmacol. 462, 83-89.
154. Yuan, H., Sarre, S., Ebinger, G., and Michotte, Y. (2005). Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J. Neurosci. Methods 144, 35-45.
155. Zarow, C., Lyness, S. A., Mortimer, J. A., and Chui, H. C. (2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337-341.